These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29667947)

  • 1. Ibalizumab-uiyk (Trogarzo) for multidrug-resistant HIV.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):68-69. PubMed ID: 29667947
    [No Abstract]   [Full Text] [Related]  

  • 2. Two new drugs for HIV infection.
    Med Lett Drugs Ther; 2008 Jan; 50(1277):2-4. PubMed ID: 18197163
    [No Abstract]   [Full Text] [Related]  

  • 3. PRO 140--a novel CCR5 co-receptor inhibitor.
    Khatib N; Das S
    Recent Pat Antiinfect Drug Discov; 2010 Jan; 5(1):18-22. PubMed ID: 19807678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibalizumab: First Global Approval.
    Markham A
    Drugs; 2018 May; 78(7):781-785. PubMed ID: 29675744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection.
    Beccari MV; Mogle BT; Sidman EF; Mastro KA; Asiago-Reddy E; Kufel WD
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty.
    Sheikh V; Murray JS; Sherwat A
    N Engl J Med; 2018 Aug; 379(7):605-607. PubMed ID: 30110580
    [No Abstract]   [Full Text] [Related]  

  • 7. Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection.
    Blair HA
    Drugs; 2020 Feb; 80(2):189-196. PubMed ID: 31970712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug Resistant HIV Drug Lauded, But Clinical Foundation Not Very Deep.
    Morrow T
    Manag Care; 2018 Jun; 27(6):31-33. PubMed ID: 29989910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibalizumab.
    Bettiker RL; Koren DE; Jacobson JM
    Curr Opin HIV AIDS; 2018 Jul; 13(4):354-358. PubMed ID: 29746266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibalizumab for the treatment of multidrug-resistant HIV-1 infection.
    Rizza SA; Bhatia R; Zeuli J; Temesgen Z
    Drugs Today (Barc); 2019 Jan; 55(1):25-34. PubMed ID: 30740610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients.
    Hasson H; Biswas P; Galli L; Burastero SE; Danise A; Bigoloni A; Carini E; Locatelli M; Vecchi A; Lazzarin A; Castagna A
    New Microbiol; 2006 Oct; 29(4):223-30. PubMed ID: 17201088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of darunavir and enfuvirtide in a pregnant woman.
    Sued O; Lattner J; Gun A; Patterson P; Abusamra L; Cesar C; Fink V; Krolewiecki A; Cahn P
    Int J STD AIDS; 2008 Dec; 19(12):866-7. PubMed ID: 19050223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity.
    Song R; Oren DA; Franco D; Seaman MS; Ho DD
    Nat Biotechnol; 2013 Nov; 31(11):1047-52. PubMed ID: 24097413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short communication: evaluation of the effect of enfuvirtide in 11 HIV-1 vertically infected pediatric patients outside clinical trials.
    Palladino C; Briz V; González-Tomé MI; León Leal JA; Navarro ML; de José MI; Ramos JT; Muñoz-Fernández MA
    AIDS Res Hum Retroviruses; 2010 Mar; 26(3):301-5. PubMed ID: 20334565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibalizumab-uiyk as a bridge therapy for a patient with drug-resistant HIV-1 infection receiving chemotherapy: A case report.
    Dickter JK; Martin AL; Ho S; Ross JA; Shouse GP
    J Clin Pharm Ther; 2021 Aug; 46(4):1185-1187. PubMed ID: 34111306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression.
    Santos JR; Llibre JM; Ferrer E; Domingo P; Imaz A; Moltó J; Martin-Iguacel R; Caum C; Podzamczer D; Clotet B
    HIV Clin Trials; 2009; 10(6):432-8. PubMed ID: 20133273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs.
    Pozniak A
    J HIV Ther; 2008 Jun; 13(2):27-33. PubMed ID: 18953271
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.